Adagene Inc. announced on July 15, 2025, that it is seeking regulatory approval from the FDA for its therapy, which involves collaboration with Merck.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Adagene Inc. announced on July 15, 2025, that it is seeking regulatory approval from the FDA for its therapy, which involves collaboration with Merck.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- Eli Lilly and Merck are combining therapies in clinical trials.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
Coverage
Newest first; wire copies grouped- GlobeNewswireAdagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - Alignment ga